459:. Extract the pertinent information rather than just dumping low-level facts in a big list. For example, a long list of side effects is largely useless without some idea of which are common or serious. It can be illuminating to compare the drug with others in its class, or with older and newer drugs. Do not include dose or titration information except when they are extensively discussed by secondary sources, necessary for the discussion in the article, or when listing equivalent doses between different pharmaceuticals. Knowledge is also not an instruction manual or textbook and should not include instructions, advice (legal, medical or otherwise) or "how-to"s (see
102:
1395:
53:
1018:
Include information on the chemical structure, stereochemistry, and chemical composition of the drug (e.g., free base, hydrochloride salt, etc.), physical characteristics, and notable chemical properties. Basic physicochemical properties such as melting pointing, solubility and other raw data should
589:
Where ambiguity exists as to the order in which drugs should be listed, the
British Approved Name for the combination (if one exists) or the order used by the manufacturer of the innovator brand should be used as a guide. For example, although no BAN exists for isosorbide dinitrate/hydralazine above,
932:
of the drug (for example which receptor subtype, ion channel population, isozyme, etc. the drug binds to) and if the drug blocks or activates that target. If relevant, mention what endogenous substance (neurotransmitter, hormone, substrate, etc.) is mimicked or blocked by the drug. Also describe
1052:
When writing about the history of the drug, only include this section if a sufficient amount of information on the drug's origin and/or first synthesis is available. If so, there should be a timeline of first synthesis, approval dates (U.S., Europe, UK, etc.), when marketing stopped or ownership
801:
This section details what forms the drug is available in. Information includes route of administration (e.g. oral, i.v., i.m., rectal, parenteral, intranasal. Oral forms of administration should be differentiated: tablets, crushable tablets, capsules (containing powder, gel, or sprinkle beads),
740:(USAN), development codenames, and the pronunciation -- that content can go in the infobox or the body of the article. In parentheses, list the main or initial brand names for the drug. If there are more than a few brand names, it is best to list these separately in the body of the article.
869:
List the adverse effects (including withdrawal symptoms, if applicable), as well as whether they are common, uncommon, or rare. The latter should only be mentioned if severe or otherwise notable. If possible, use specific statistics (be sure to cite sources!). Use side effect percentage with
728:. If a substance is used primarily as a drug, it should be noted so. Most of our readers access Knowledge on mobile devices, and excess naming becomes clutter that prevents swift access to the heart of the matter. Therefore, avoid cluttering the lead with multiple alternatives to the
491:
states that, "naming should give priority to what the majority of
English speakers would most easily recognize, with a reasonable minimum of ambiguity, while at the same time making linking to those articles easy and second nature." To that end, the World Health Organization
434:
The order of sections used in this guideline is recommended for readability and consistency between articles. The order suggested below is to emphasize information sought after by general readers. If you disagree with part of the style guide, please discuss changes on the
594:
to the chosen name. Non-standard proprietary combination preparations are discouraged, and fall outside the scope of this guideline. For example, a hypothetical "paracetamol/dextromethorphan/pseudoephedrine" page is discouraged and does not fall under this guideline.
778:
This section should go into further detail regarding what the medication is used for (for each major indication). Take special care with regulatory terms; since drug approvals vary from country to country, so does the distinction between approved and
528:, in which case the INN consists of two parts: the cation and the anion name. For example, "chlorphenamine maleate" is the INN modified (INNM) of a common first-generation antihistamine, thus the INN of the active moiety is used as the page title:
723:
without introducing errors or ambiguity. It is also reasonable to have the lead introduce content in the same order as the body of the text. In articles about drugs, they should describe the drug in question, as well as what it does. Note any
610:
Nonproprietary names are common nouns and hence should be lower case except in titles, the beginning of sentences, and in other situations that require capitalization. In contrast, trade names are proper nouns and should always be capitalized.
471:, intended to be read by the lay public so it is important to make technical material as accessible as possible to a wide audience but at the same time, not reducing the value of the article to more technical readers including
1225:
185:
1205:
Look for similar articles to check for what categories they belong to and add the article to any appropriate categories. If no similar articles can be found, add the article to any categories that seem appropriate. See
718:
is defined as "the section before the first headline. The table of contents, if displayed, appears between the lead section and the first headline." The lead of an article, if not the entire article, should be
951:
This section should describe the clinically relevant pharmacokinetic parameters of a drug or active metabolites and the mechanisms of clearance (e.g., specific enzyme systems or transporters). List the
539:
A page should mention other names in the lead section, in boldface, and the naming reference noted if possible. Those other common names of the drug should redirect to that page. For example, the page
1263:
For articles on agents that are primarily recreational in use a section on the "Effects" of the agent early is recommended. This may be followed by sections on "Recreational uses" and "Medical uses".
1370:
1373:
contains an updated list of of articles that don't follow this article title guideline and include the INN in the drugbox INN parameter; these articles are listed under the underscore section.
512:
is more appropriate. For example, "paracetamol" and "acetaminophen" are two common names for the same analgesic, and "paracetamol" is the INN. The relevant
Knowledge article has the page name
150:
233:
752:, but it should be included in every drug-related article. In the source code of the article, it appears before the article lead. It is displayed at the top-right corner of the page. For
1187:
This is not a section — it comes after the last section in the article — but it is nonetheless an important part of any drug article. Most families of drugs already have a template; see
937:
pathways are impacted, what genes are up or down regulated, etc.) and how modulating the activity of the target ultimately translates into the desired therapeutic effect (that is, the
339:
582:("/") character. For example, the standard combination of isosorbide dinitrate and hydralazine, used to treat congestive heart failure in African Americans, is described in the page
1152:
263:
145:
1321:
There is currently no consensus whether codes for drug combinations should be added to articles about single drugs. If you do so, add "(combination with ])" or the like, using the
1156:
162:
40:
315:
436:
217:
1207:
303:
256:
720:
157:
310:
270:
212:
191:
536:. If an INN has yet to be formally listed by WHO, but a proposed INN (pINN) exists, it is considered to be equivalent to the INN with respect to this guideline.
291:
181:
1188:
599:
298:
284:
277:
204:
332:
237:
400:. It contains the articles naming conventions and the general recommended outline of an article, as well as useful information to bring an article to
802:
enteric-coated or slow-release tables/capsules, syrup, sugar-free liquid, or powder (soluble or for suspension). Only include this section if the
199:
126:
791:
dosage information is not recommended as it may be construed as medical advice and be easily subject to vandalism or uninformed good-faith edits.
325:
1006:
This section should cover any known drug-microbiota interactions, particularly ones that occur in the gut for orally administered medications.
1406:
941:, for example vasodilation resulting in decreased blood pressure). If the mechanism of action is not known, this section should state that.
620:
508:(INN), also known as recommended International Nonproprietary Name (rINN), if one exists, except in unusual circumstances where another
77:
905:
This section should note what other drugs/food interact with the drug in question, and what effect(s) are produced by this interaction.
397:
121:
107:
17:
1459:
1454:
729:
505:
493:
412:
82:
36:
855:
Under what circumstances should the drug in question not be used? Distinguish relative and absolute contraindications if possible.
657:
Full instructions are available on the page for each infobox. A suitable picture for the infobox is encouraged. For drugs, the 2D
423:(USAN) variant may also be mentioned. The initial brand name(s) follows, in parentheses. All drug names should be in boldface per
583:
705:
Primarily medication-related pages should contain information organized into the following sections, with attention to order.
23:
1031:
653:, the chemical infobox is possibly more appropriate for research drugs for which little or no clinical data is yet available
488:
464:
1215:
737:
1148:
1133:
Avoid the See also section when possible; prefer wikilinks in the main article and navigation templates at the end.
678:
548:
448:
420:
590:
the manufacturer of the innovator brand "BiDil" lists the constituents in that order. Alternative names should be
666:
644:
86:
65:
1143:
These are essential. Unreferenced "information" may be deleted or moved to the talk page. As guidelines we have
686:
662:
559:
558:. All issues of the journal, and lists of all proposed and recommended INNs from 1955 onward, are available in
1211:
961:
957:
563:
1144:
733:
631:
416:
71:
578:, this guideline encourages the use of page titles containing the active constituents separated by the
870:
placebo/control vs. percentage with drug/experimental. Always include adverse events highlighted with
969:
965:
761:
509:
1155:. In short: The popular press is generally not a reliable source for medicine information. See also
1081:
If applicable, describe recreational usage (i.e. abuse) and other illicit usage (for example, using
934:
925:
525:
424:
725:
658:
591:
533:
532:. On the other hand, tiotropium is a quaternary ammonium cation, so the INN used as the title is
353:
1403:
1243:
should be strictly summarized, with clear linking to their main articles for further reading.
1240:
1170:
989:
929:
1235:, the content should primarily focus on what particular effects the combination has, such as
1232:
1064:
745:
575:
61:
1296:
977:
973:
953:
547:, which notes in the first sentence that "salbutamol" is the INN and "albuterol" is the
1086:
938:
715:
669:
is acceptable. The easiest way to populate the drugbox and protein templates is to use
529:
472:
169:
1448:
1365:
1357:
1082:
884:
This section describes symptoms of overdose, what to do in case of overdose, and the
871:
780:
765:
517:
460:
1303:
1286:
1236:
1192:
670:
520:. If a compound exists in salt form, then the INN is the name of the active moiety
468:
405:
401:
244:
1361:
1275:
650:
637:
513:
1400:
Scientific Style and Format: the CBE Manual for
Authors, Editors and Publishers
101:
1353:
1252:
544:
476:
428:
393:
1115:
Ongoing investigations into a medication that have not reached clinical usage
1349:
1157:
Knowledge:Manual of Style (medicine-related articles)#Citing medical sources
540:
1368:, which redirect to an article title that differs from the INN listed here.
74:
on how to format and present article content within their area of interest.
1226:
Knowledge talk:WikiProject
Pharmacology/General/Main sections of drug page
1095:
Global sales, distribution, cost in major
English speaking countries, etc.
783:. A more detailed description of drug regulation should go to the section
411:
The article title and the first name to mention in the lead should be the
96:
1271:
753:
467:). Finally it is important to keep in mind that we are writing a general
993:
985:
981:
574:
Since no international convention exists to guide naming of standard
1218:
for templates to choose from. Language links go right to the bottom.
1278:
should be added to the drugbox. If there is more than one, use the
554:
INNs are published by the World Health
Organization in the journal
579:
885:
816:
Include one or more of the following subsections if appropriate:
389:
52:
1302:. This ensures proper linking of the codes – to the ATC lists (
697:
The ordering of section may vary depending on the article type
600:
Knowledge:WikiProject
Pharmacology/Workspace#Naming conventions
1307:
47:
24:
Knowledge:WikiProject Drugs/General/Main sections of drug page
1371:
Category:Infobox drug articles with non-default infobox title
1075:
Describe regulatory status in different regions of the world.
996:). Some of this information is also included in the drugbox.
933:
the downstream consequences of modulating that target (what
682:
100:
1101:
Brand names of the medication and manufacturer, if notable.
674:
625:
Infoboxes should be used where appropriate. These include
396:
articles on
Knowledge, as established by the consensus of
1169:
Avoid this section if possible, since it is a magnet for
456:
452:
1195:
for an immunosuppressant) for which template(s) to use.
375:
368:
361:
1153:
Knowledge:Reliable sources (medicine-related articles)
1402:(6th ed.). Cambridge: Cambridge Univ. Press. p. 324.
1123:
If different from use in humans or otherwise notable.
1107:
Controversies surrounding the medication, if notable.
41:
Knowledge:Manual of Style (medicine-related articles)
1214:, if applicable, goes below the category links. See
806:
field of the drugbox does not provide enough space.
496:(INN) should normally be used as the article name.
447:Try to avoid cloning drug formularies such as the
70:It contains the advice or opinions of one or more
1310:database. Recommended sorting of multiple codes:
1208:Knowledge:WikiProject Pharmacology/Categorization
504:A drug article should be titled according to its
598:Tasks related to this guideline can be found at
1328:Drugs without an ATC(vet) code should have set
980:and the major metabolizing enzymes for example
333:
8:
1317:Within these two groups, sort alphabetically
1189:Knowledge:WikiProject Pharmacology/Templates
1438:, and may also be found in the page's URL.
431:and family and the main therapeutic uses.
340:
326:
891:(median lethal dose), if it is available.
1173:. Links to on-line pharmacies and blogs
1396:"Chaper 19: Drugs and Pharmacokinetics"
1386:
1341:
1027:(only necessary for articles tagged by
760:. More information can be found at the
1282:parameter together with the templates
1251:Add a section listing "Agents" in the
1425:, and may be found in the page's URL.
7:
1191:and the appropriate ATC list (e. g.
685:for the protein and enter the ID in
1394:CBE Style Manual Committee (2002).
621:Knowledge:Manual of Style/Infoboxes
1063:Don't use this section for adding
757:
673:template-filling web site. Search
415:(INN) of the drug; see below. The
398:Knowledge:WikiProject Pharmacology
87:thoroughly vetted by the community
31:
18:Knowledge:WikiProject Pharmacology
1210:for categories to choose from. A
972:, major metabolic pathways (e.g.
924:If known, describe the molecular
677:for the drug and enter the ID in
506:International Nonproprietary Name
494:International Nonproprietary Name
413:International Nonproprietary Name
584:Isosorbide dinitrate/hydralazine
51:
1421:DrugBank IDs follow the format
1:
1314:ATC codes before ATCvet codes
1201:Categories and language links
721:written as simply as possible
83:Knowledge policy or guideline
465:Knowledge:Medical disclaimer
1434:HUGO IDs follow the format
1348:Notable exceptions include
1216:Category:Pharmacology stubs
1085:to facilitate robbery/as a
872:mandated prominent warnings
738:United States Approved Name
1476:
1149:Knowledge:Reliable sources
768:is able to provide images.
618:
570:Standard combination drugs
549:United States Adopted Name
451:and online resources like
421:United States Adopted Name
351:
1239:. Regular effects of the
1019:be placed in the drugbox.
665:format is preferred, but
250:
227:
172:
168:
115:
99:
1460:WikiProject Pharmacology
1455:WikiProject style advice
1306:etc.) as well as to the
1228:for related discussion.
1041:Detection in body fluids
804:Routes of administration
928:including the specific
1183:Navigational templates
958:volume of distribution
762:template documentation
748:This is not a section
543:redirects to the page
443:General considerations
234:Requested articles (1)
105:
1145:Knowledge:Attribution
1032:WikiProject Chemicals
734:British Approved Name
619:Further information:
417:British Approved Name
388:for the structure of
299:Resources for editors
104:
85:, as it has not been
1002:Pharmacomicrobiomics
812:Specific populations
556:WHO Drug Information
516:, and a redirect at
487:Knowledge policy on
116:General information
1259:Recreational agents
1059:Society and culture
935:signal transduction
926:mechanism of action
916:Mechanism of action
526:quaternary compound
500:Articles to use INN
1241:active ingredients
827:Labor and delivery
732:name, such as the
726:black box warnings
534:Tiotropium bromide
479:, and scientists.
264:Structure diagrams
106:
1408:978-0-521-47154-1
1330:ATC_prefix = none
1233:combination drugs
1053:transferred, etc.
990:monoamine oxidase
930:biological target
897:Drug interactions
851:Contraindications
576:combination drugs
489:naming convention
350:
349:
223:
222:
95:
94:
22:(Redirected from
1467:
1439:
1437:
1432:
1426:
1424:
1419:
1413:
1412:
1391:
1374:
1346:
1331:
1324:
1323:ATC_supplemental
1301:
1295:
1291:
1285:
1281:
1280:ATC_supplemental
1079:Recreational use
1036:
1030:
947:Pharmacokinetics
920:Pharmacodynamics
787:, further down.
648:
645:Infobox chemical
635:
406:featured article
378:
371:
364:
342:
335:
328:
170:
146:Reliable sources
97:
81:is not a formal
78:This information
55:
48:
27:
1475:
1474:
1470:
1469:
1468:
1466:
1465:
1464:
1445:
1444:
1443:
1442:
1435:
1433:
1429:
1422:
1420:
1416:
1409:
1393:
1392:
1388:
1383:
1378:
1377:
1347:
1343:
1338:
1329:
1322:
1299:
1293:
1289:
1283:
1279:
1269:
1261:
1249:
1067:to the article.
1034:
1028:
962:protein binding
954:bioavailability
889:
861:Adverse effects
797:Available forms
703:
695:
642:
629:
623:
617:
608:
572:
502:
485:
473:medical doctors
445:
427:. Indicate the
382:
381:
374:
367:
360:
356:
346:
213:Editor outreach
134:Manual of Style
91:
90:
35:For the parent
29:
28:
21:
20:
12:
11:
5:
1473:
1471:
1463:
1462:
1457:
1447:
1446:
1441:
1440:
1427:
1414:
1407:
1385:
1384:
1382:
1379:
1376:
1375:
1369:
1340:
1339:
1337:
1334:
1319:
1318:
1315:
1268:
1265:
1260:
1257:
1248:
1245:
1222:
1221:
1220:
1219:
1198:
1197:
1196:
1180:
1179:
1178:
1165:External links
1162:
1161:
1160:
1136:
1135:
1134:
1126:
1125:
1124:
1119:Veterinary use
1116:
1110:
1109:
1108:
1102:
1096:
1090:
1087:date rape drug
1076:
1069:
1068:
1056:
1055:
1054:
1045:
1044:
1043:
1038:
1021:
1020:
1011:
1010:
1009:
1008:
1007:
999:
998:
997:
944:
943:
942:
939:mode of action
908:
907:
906:
894:
893:
892:
887:
877:
876:
875:
858:
857:
856:
848:
847:
846:
845:
844:
842:In the elderly
839:
834:
829:
824:
818:
817:
809:
808:
807:
793:
792:
781:off-label uses
771:
770:
769:
742:
741:
702:
699:
694:
691:
655:
654:
649:– for example
640:
636:– for example
616:
613:
607:
606:Capitalization
604:
571:
568:
530:Chlorphenamine
501:
498:
484:
481:
444:
441:
380:
379:
372:
365:
357:
352:
348:
347:
345:
344:
337:
330:
322:
319:
318:
313:
307:
306:
301:
295:
294:
288:
287:
281:
280:
274:
273:
267:
266:
260:
259:
257:Categorization
253:
252:
251:Other content
248:
247:
241:
240:
230:
229:
225:
224:
221:
220:
215:
208:
207:
202:
195:
194:
189:
177:
176:
166:
165:
160:
154:
153:
148:
142:
141:
136:
130:
129:
124:
118:
117:
113:
112:
109:
93:
92:
75:
58:
56:
46:
45:
30:
15:
14:
13:
10:
9:
6:
4:
3:
2:
1472:
1461:
1458:
1456:
1453:
1452:
1450:
1431:
1428:
1418:
1415:
1410:
1405:
1401:
1397:
1390:
1387:
1380:
1372:
1367:
1366:tenamfetamine
1363:
1359:
1358:metamfetamine
1355:
1351:
1345:
1342:
1335:
1333:
1326:
1316:
1313:
1312:
1311:
1309:
1305:
1298:
1288:
1277:
1273:
1266:
1264:
1258:
1256:
1254:
1246:
1244:
1242:
1238:
1234:
1229:
1227:
1217:
1213:
1212:stub template
1209:
1204:
1203:
1202:
1199:
1194:
1190:
1186:
1185:
1184:
1181:
1176:
1172:
1168:
1167:
1166:
1163:
1158:
1154:
1150:
1146:
1142:
1141:
1140:
1137:
1132:
1131:
1130:
1127:
1122:
1121:
1120:
1117:
1114:
1111:
1106:
1105:Controversies
1103:
1100:
1097:
1094:
1091:
1088:
1084:
1083:flunitrazepam
1080:
1077:
1074:
1071:
1070:
1066:
1062:
1061:
1060:
1057:
1051:
1050:
1049:
1046:
1042:
1039:
1033:
1026:
1023:
1022:
1017:
1016:
1015:
1012:
1005:
1004:
1003:
1000:
995:
991:
987:
983:
979:
975:
971:
967:
963:
959:
955:
950:
949:
948:
945:
940:
936:
931:
927:
923:
922:
921:
917:
914:
913:
912:
909:
904:
903:
902:
898:
895:
890:
883:
882:
881:
878:
873:
868:
867:
866:
862:
859:
854:
853:
852:
849:
843:
840:
838:
835:
833:
830:
828:
825:
823:
820:
819:
815:
814:
813:
810:
805:
800:
799:
798:
795:
794:
790:
786:
782:
777:
776:
775:
772:
767:
766:User:Fuzzform
763:
759:
755:
751:
747:
744:
743:
739:
735:
731:
727:
722:
717:
713:
712:
711:
708:
707:
706:
700:
698:
692:
690:
688:
684:
680:
676:
672:
668:
664:
660:
652:
646:
641:
639:
633:
628:
627:
626:
622:
614:
612:
605:
603:
601:
596:
593:
587:
585:
581:
577:
569:
567:
565:
561:
557:
552:
550:
546:
542:
537:
535:
531:
527:
523:
519:
518:Acetaminophen
515:
511:
507:
499:
497:
495:
490:
482:
480:
478:
474:
470:
466:
462:
458:
454:
450:
442:
440:
438:
432:
430:
426:
422:
418:
414:
409:
407:
403:
399:
395:
391:
387:
377:
373:
370:
366:
363:
359:
358:
355:
343:
338:
336:
331:
329:
324:
323:
321:
320:
317:
314:
312:
309:
308:
305:
302:
300:
297:
296:
293:
290:
289:
286:
283:
282:
279:
276:
275:
272:
269:
268:
265:
262:
261:
258:
255:
254:
249:
246:
243:
242:
239:
235:
232:
231:
226:
219:
216:
214:
210:
209:
206:
203:
201:
197:
196:
193:
190:
187:
183:
179:
178:
175:
171:
167:
164:
161:
159:
158:Popular pages
156:
155:
152:
149:
147:
144:
143:
140:
137:
135:
132:
131:
128:
125:
123:
120:
119:
114:
111:
103:
98:
88:
84:
80:
79:
73:
69:
67:
63:
57:
54:
50:
49:
44:
42:
38:
33:
32:
25:
19:
1436:hgnc_id=xxxx
1430:
1417:
1399:
1389:
1344:
1327:
1320:
1304:ATC code A01
1276:ATCvet codes
1270:
1262:
1250:
1247:Drug classes
1237:drug synergy
1230:
1223:
1200:
1193:ATC code L04
1182:
1174:
1164:
1138:
1128:
1118:
1112:
1104:
1098:
1092:
1078:
1073:Legal status
1072:
1058:
1047:
1040:
1024:
1013:
1001:
946:
919:
915:
911:Pharmacology
910:
901:Interactions
900:
896:
879:
865:Side effects
864:
860:
850:
841:
836:
831:
826:
821:
811:
803:
796:
788:
785:Legal status
784:
774:Medical uses
773:
749:
716:lead section
709:
704:
696:
681:, or search
656:
632:Infobox drug
624:
609:
597:
588:
573:
555:
553:
538:
521:
503:
486:
483:Article name
469:encyclopedia
461:WP:NOT#HOWTO
446:
433:
425:WP:BOLDTITLE
410:
402:good article
385:
383:
369:WP:DRUGGUIDE
311:Participants
245:Cleanup list
228:How to help
173:
138:
133:
122:Project page
110:Pharmacology
76:
72:WikiProjects
59:
34:
1362:diamorphine
1325:parameter.
1224:Please see
1177:be deleted.
1099:Brand names
837:In children
701:Medications
651:ICI-118,551
638:Paracetamol
564:WHO website
514:Paracetamol
510:common name
477:pharmacists
386:advice page
384:This is an
376:WP:PHARMMOS
362:WP:DRUGLIKE
271:Photographs
174:Departments
108:WikiProject
60:This is an
1449:Categories
1381:References
1354:amfetamine
1139:References
592:redirected
545:Salbutamol
429:drug class
394:medication
292:Historical
182:Assessment
1423:APRDxxxxx
1350:lysergide
1272:ATC codes
1267:ATC codes
1093:Economics
1065:WP:TRIVIA
1025:Synthesis
1014:Chemistry
970:clearance
966:half-life
832:Lactation
822:Pregnancy
754:ATC codes
736:(BAN) or
687:this page
679:this page
671:Diberri's
659:structure
615:Infoboxes
541:Albuterol
457:Drugs.com
437:talk page
419:(BAN) or
354:Shortcuts
285:Workspace
278:Templates
37:guideline
1129:See also
1113:Research
978:phase II
880:Overdose
789:Detailed
693:Sections
675:DrugBank
551:(USAN).
524:it is a
463:and the
408:status.
200:Research
1048:History
976:and/or
974:phase I
746:Drugbox
562:on the
1364:, and
1297:ATCvet
994:UGT2B7
986:CYP3A4
982:CYP2D6
756:, see
750:per se
522:unless
453:RxList
39:, see
1336:Notes
1253:class
758:below
580:slash
66:style
62:essay
16:<
1404:ISBN
1292:and
1274:and
1231:For
1175:will
1171:spam
1151:and
714:The
710:Lead
683:HUGO
455:and
392:and
390:drug
316:talk
304:talk
218:talk
205:talk
192:talk
163:talk
151:talk
139:talk
127:talk
1308:WHO
1287:ATC
918:or
899:or
863:or
730:INN
667:PNG
663:SVG
661:in
560:PDF
449:BNF
404:or
238:(2)
186:Log
64:on
1451::
1398:.
1360:,
1356:,
1352:,
1332:.
1300:}}
1294:{{
1290:}}
1284:{{
1255:.
1147:,
1089:).
1035:}}
1029:{{
992:,
988:,
984:,
968:,
964:,
960:,
956:,
888:50
886:LD
764:.
689:.
647:}}
643:{{
634:}}
630:{{
602:.
586:.
566:.
475:,
439:.
236:/
211:→
198:→
188:)
180:→
1411:.
1159:.
1037:)
874:.
341:e
334:t
327:v
184:(
89:.
68:.
43:.
26:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
